CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases

Biocon  /  News – Posts  /  Press Releases

Biocon and Mylan Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab

  • Posted by: BIOCON

Biocon and Mylan Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim

  • Posted by: BIOCON

Biocon Q1FY19 Revenue Rs 1,193 Cr, Up 21%; EBITDA Up 25% at Rs 307 Cr; Net Profit Up 47% at Rs 120 Cr

  • Posted by: BIOCON

Kiran Mazumdar-Shaw Elected Full-Term Member of the Board of Trustees of MIT, USA

  • Posted by: BIOCON

U.S. FDA Approves Mylan and Biocon’s Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®

  • Posted by: BIOCON

Tata Memorial Hospital Team Presents Biocon’s Nimotuzumab Study Results at ASCO Annual Meeting 2018

  • Posted by: BIOCON

Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herceptin®, approved by US FDA

  • Posted by: BIOCON

Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr

  • Posted by: BIOCON

Kiran Mazumdar-Shaw #1 Business Captain in ‘The Medicine Maker 2018 Power List’

  • Posted by: BIOCON

Mylan and Biocon Receive Approvals from the European Commission and TGA, Australia for Semglee™ Biosimilar Insulin Glargine

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>